Due to their well-established fracture risk reduction, bisphosphonates are the most frequently used therapeutic agent to treat osteoporosis. Bisphosphonates reduce fracture risk by suppressing bone resorption, but the lower bone turnover could have a negative impact on bone quality at the tissue level. Here, we directly assess the structural and mechanical characteristics of cancellous bone from the lumbar vertebrae (L5) in non-treated osteoporotic controls (n = 21), mid-term alendronate-treated osteoporotic patients (n = 6), and long-term alendronate-treated osteoporotic patients (n = 7). The strength and toughness of single trabeculae were evaluated, while the structure was characterised through measurements of microdamage accumulation, mineralisation distribution, and histological indices. The alendronate-treated cases had a reduced eroded surface (ES/BS, p < 0.001) and a higher bone mineralisation in comparison to non-treated controls (p = 0.037), which is indicative of low turnover associated with treatment. However, the amount of microdamage and the mechanical properties were similar among the control and treatment groups. As the tissue mineral density (TMD) increased significantly with alendronate treatment compared to nontreated osteoporotic controls, the reduction in resorption cavities could counterbalance the higher TMD allowing the alendronate-treated bone to maintain its mechanical properties and resist microdamage accumulation. A multivariate analysis of the possible predictors supports the theory that multiple factors (e.g., body mass index, TMD, and ES/BS) can impact the mechanical properties. Our results suggest that long-term alendronate treatment shows no adverse impact on mechanical cancellous bone characteristics.
Introduction
Vertebral fractures are the most common fragility fractures in patients with osteoporosis and potentially lead to adverse effects, such as acute or chronic back pain, disability, and impairment in quality of life (Oleksik et al., 2000; Krause et al., 2012b) . Currently, bisphosphonates represent the most frequently used therapeutic agent to prevent osteoclastinduced bone loss, such as in post-menopausal osteoporosis. An average bisphosphonate treatment duration of 3 to 4 years is associated with a significant fracture risk reduction of up to 50 % for vertebral fractures and up to 55 % for non-vertebral fractures (Black et al., 1996; Cummings et al., 1998; Harris et al., 1999) ; however, bisphosphonate treatment is often continued indefinitely. As the main effect of bisphosphonates is based on a continuous suppression of bone turnover, which could impair the structure and mechanical properties of the remaining bone tissue, there are reservations in the medical community regarding the use of bisphosphonates as a long-term therapy.
Currently, only a few clinical studies analyse the clinical consequences of long-term bisphosphonate therapy in humans (Bone et al., 2004; Black et al., 2006; Black et al., 2012) . Two studies have shown that continued bisphosphonate treatment over the average duration of 3-5 years lowers the risk of vertebral fractures and preserves the increased areal bone mineral density (aBMD) compared to patients who discontinue therapy after the average duration (Black et al., 2006; Black et al., 2012) . Other than the benefits of a higher aBMD, factors relating to bone quality (e.g., size, geometry, microarchitecture or microdamage accumulation) have not been completely evaluated although they could also explain the fracture risk reduction associated with bisphosphonate treatment (Ammann and Rizzoli, 2003) . Some effects of long-term bisphosphonate therapy may be detrimental. For instance, an increase in the average degree of mineralisation due to suppression of bone turnover could lead to microdamage accumulation, resulting in reduced bone strength and toughness (Boivin et al., 2000; Roschger et al., 2001; Nyman et al., 2004 ). An accumulation of microdamage due to the suppression of bone turnover is well established in animal studies (Mashiba et al., 2000; Mashiba et al., 2001; Allen et al., 2006) , while data from human bone are inconsistent (Chapurlat et al., 2007; Stepan et al., 2007) .
Nonetheless, even if microdamage increasingly occurs with long-term bisphosphonate therapy, the impact of M Krause et al. Long-term alendronate treatment long-term bisphosphonate therapy on mechanical bone tissue characteristics and their clinical importance is largely unknown (Allen and Burr, 2011) . In principle, bisphosphonate therapy may result in improved bone characteristics accompanied by changes in Young's modulus (Ding et al., 2003; Day et al., 2004) and reduced toughness (Komatsubara et al., 2003; Allen and Burr, 2007; Wang et al., 2008) . While these principles have largely been established through animal models, studies on humans with severely suppressed bone turnover due to long-term bisphosphonate therapy have been more conflicting, indicating both improved (Tjhia et al., 2011) and deteriorated (Bala et al., 2011) mechanical properties in cortical and cancellous bone. Indeed, inter-individual variations may explain the fracture risk reduction in some patients and the deterioration in mechanical properties of other patients. Specifically, patients with atypical femoral fractures (AFF) have been repeatedly documented after long-term bisphosphonate therapy (Vaishya et al., 2013; Bottai et al., 2014; Zanchetta et al., 2014) . A recent study using microindentation found deteriorated bone material properties in patients with both typical and atypical hip fractures in comparison to untreated controls. However, patients with long-term bisphosphonate therapy were not statistically different from untreated controls, which suggests that bisphosphonate treatment itself may not necessarily impair bone material properties (Guerri-Fernandez et al., 2013) .
To further investigate the complex effects of long-term bisphosphonate therapy, the aim of the present study was to directly assess the structural and mechanical characteristics of human cancellous bone. As bisphosphonates affect bone tissue properties on different structural levels, the effects of bisphosphonate treatment duration are investigated at the single trabeculae level by quantifying microdamage accumulation, bone turnover activity, bone tissue mineralisation and mechanical properties.
Materials and Methods

Materials
In this study, 35 patients were included from the ex vivo "Biomechanically founded individualized osteoporosis assessment and treatment (BioAsset)" study with the goal to elucidate the effects of bisphosphonate treatment on bone by combining imaging and biomechanical techniques (Glüer et al., 2013; Krause et al., 2014; Museyko et al., 2014) . Inclusion criteria were females with postmenopausal osteoporosis, which was diagnosed according to the World Health Organization definition, with a lumbar or femoral areal bone mineral density (aBMD) T-Score of -2.5 or less assessed by dual x-Ray absorptiometry (DXA). Exclusion criteria included bone cancer, immobility >1 year, renal transplantation or renal insufficiency III, strontium or fluoride therapy, specific anti-resorptive medication other than bisphosphonates and bisphosphonate therapy <1 year. Informed consent was obtained from the family members after comprehensive information on all related issues. The study was approved by the Ethics Committee of the Hamburg Chamber of Physicians (PV3486). Thirtyfive patients matching the inclusion criteria were included. One patient had to be excluded due to lumbar spinal fusion. Therefore, the lumbar spinal column was obtained from 34 patients (median age: 83 years [range: 65 to 90 years]) during autopsy at the Department of Forensic Medicine, University Medical Centre Hamburg-Eppendorf (Fig. 1 ). All patients were categorised according to bisphosphonate treatment duration prior to death as follows:
• Control group (n = 21), females with diagnosed osteoporosis but no documented history of bisphosphonate treatment • Mid-term bisphosphonate-treated group (n = 6), females taking bisphosphonates for a duration of 1-5 years (mean 2.16 ± 0.99 years) • Long-term bisphosphonate-treated group (n = 7), females taking bisphosphonates for a duration of 6 years. The treatment for all patients on bisphosphonate therapy consisted of weekly alendronate.
Preparation of single trabeculae
To prepare single trabeculae for mechanical testing, the L5 vertebra was dissected along the sagittal direction in three sections (Fig. 1A) . The trabeculae were singularised according to methods previously described in detail (Busse et al., 2009) . Briefly, the central 5 mm slice of L5 was soaked in hydrogen peroxide for 8 h and rinsed with demineralised water to remove soft tissue. According to guidelines established by previous studies (Busse et al., 2009) , trabeculae were removed from defined regions within the section. At least 20 single, rod-like trabeculae were harvested from each specimen using a headset magnifier (2.3, Carl Zeiss, Jena, Germany) and a mini scalpel (No. 11, Bahya, Tuttlingen, Germany) . To ensure that only intact trabeculae were tested, the structural integrity was examined in a polarised light microscope.
Biomechanical testing
The strength of single trabeculae from the L5 vertebrae was assessed via three-point bending tests using a materials testing device with a 10 N force sensor (Z.2.5/TN1S, Zwick/Roell, Ulm, Germany). Prior to the testing procedure (Busse et al., 2009) , appropriate trabeculae were identified. Ideally, only trabeculae that are precisely cylindrically shaped should be tested. Therefore, in accordance with previous studies, trabeculae with a maximum ratio of 1:1.3 between minor and major cross-sectional axis were included (Busse et al., 2009 ). Additionally, the tested trabeculae had a minimum thickness of 90 µm. All dimensions were determined with a stereomicroscope (SZH-ILLD, Olympus, Osaka, Japan). The specimens were dried to ensure that no adhesion phenomena occurred during the mounting and materials testing process. Each trabecula was placed on the custom-built three-point bending fixture. The fixture's bottom support consists of two pins with a diameter of 1.0 mm and a span of 600 μm. The top fixture consisted of a cross-head with a rounded-off tip of radius 0.1 mm that was positioned half way between the two pins on the lower fixture. The sample was placed on the bottom support's pins and load was applied to the sample via the cross-head at a speed of 2 mm/min. The M Krause et al. Long-term alendronate treatment load and displacement data were collected during testing and the bending test ended after fracture of the trabecula. The ultimate load was taken as the highest load achieved during the test and the fracture load was taken as the final load at fracture. The load and displacement curve was normalised by the specimen geometry, such that the Young's modulus (GPa), yield strength (GPa), ultimate stress (GPa) and fracture stress (GPa) could be determined from the stress-strain curve. The work to failure (W, N mm) was measured from the area under the load-displacement curve. Then, the toughness was calculated according to Mashiba et al. (Mashiba et al., 2000) by normalising the work to failure (W, N mm):
where b is the width of the trabecula. I is the cross-sectional moment of inertia with the assumption of a circular crosssection:
where r is the radius of the trabecula.
Static 3D-histomorphometry and histological analysis
The second sagittal section of the L5 vertebrae was used for histological analysis. Prior to further preparation, the vertebral remnants were scanned in a micro-computed tomography (μCT) device (μCT40, SCANCO Medical AG, Bruettisellen, Switzerland) with an in vitro scanning protocol (55 kVp, 145 μA, 200 ms integration time) resulting in an isotropic 10 μm voxel size to assess the static 3D bone histomorphometry. The following histomorphometric parameters were measured according to American Society for Bone and Mineral Research (ASBMR) standards (Dempster et al., 2013) : the vertebral BV/TV (bone volume/tissue volume, %), Tb.Th (trabecular thickness, mm), Tb.N (trabecular number, /mm), Tb.Sp 
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(trabecular separation, mm) as well as SMI (structure model index, dimensionless). Additionally, the degree of mineralisation was determined with µCT measuring the bone tissue mineral density (TMD, mg hydroxyapatite [HA]/cm 3 ) (Mulder et al., 2004; Burghardt et al., 2008) . After completion of the 3D µCT measurements, the upper half of the specimens was subjected to an undecalcified infiltration process, plastic embedded, and cut into 5 µm sections. Then, the bone sections were stained using either the von-Kossa technique, toluidine blue or Goldner trichrome, as previously described (Breer et al., 2012; Krause et al., 2012a) . The ratio of osteoid volume per bone volume (OV/BV, %), osteoid surface per bone surface (OS/ BS, %) and eroded surface (ES/BS, %) were assessed using an automated computer-assisted image analysing system (OsteoMeasure, OsteoMetrics, Decatur, GA, USA).
Microdamage assessment
To evaluate microdamage, sections from the last third of the L5 vertebrae were prepared by bulk staining using calcein (Lee et al., 2000; Aruwajoye et al., 2013) . Specimens were put in 0.9 % saline for 4 h after previous dehydration in alcohol (80 % ethanol) . Subsequently, the specimens were soaked in calcein (0.3 g/100 mL saline) for 2 h under vacuum (20 mmHg), rinsed with reverse osmosis water for another 10 min and plastic embedded. Finally, central 5 µm sections were obtained. The microdamage assessment was performed in a region of interest (ROI) of at least 5 mm 2 using the OsteoMeasure system. Microdamage was defined according to the established criteria by Burr and Stafford (Burr and Stafford, 1990; Lee et al., 2003) , including intermediate size, sharp borders with increased fluorescence, deep staining after focus changing and linear shape. ROIs were scanned for the occurrence of microdamage at 100x magnification; when microdamage was detected, the number of cracks (Cr.N) and crack length (Cr.Le, µm) were measured at 200x magnification. In accordance with previous studies, crack density (Cr. Dn, #/mm 2 ) and crack surface density (Cr.S.Dn, µm/mm 2 , Cr.N*Cr.Le/BS) were determined (Aruwajoye et al., 2013; Chapurlat et al., 2007 
Results
Concerning baseline patient characteristics, parameters such as age and body mass index, which are known to independently influence mechanical properties of bone tissue, were not significantly different among the study groups (Table 1) .
Histomorphometry
The histomorphometric analysis revealed that the overall bone volume (BV/TV) was marginally higher in controls (Table 1) due to the greater number of trabeculae (Tb.N; p = 0.019), which were slightly thinner (Tb.Th; Table 1 ) and significantly farther apart from each other (Tb.Sp; p = 0.017) in controls compared to the alendronate-treated groups. All three groups demonstrated an almost similar SMI with a tendency toward a more rod-like structure (mean: 1.92 ± 0.36). The amount of non-mineralised bone matrix (OV/BV, OS/BS) was marginally lower in patients with alendronate treatment compared to controls (OV/ (Fig. 3) ; however, the mineralisation parameters were not significantly different between the mid-and longterm alendronate-treated groups (p = 0.668).
Microdamage quantification
The crack density (i.e., the amount of microdamage per mm bone area) was not different between the control and BV p = 0.799; OS/BS p = 0.937; Fig. 2 ). However, the resorption parameters (ES/BS) provided strong evidence of the alendronate treatment as resorption cavities were significantly lower in alendronate-treated patients ( Fig. 2 ; p < 0.001). Also, the L5 vertebrae's degree of mineralisation (TMD) increased with alendronate therapy (p = 0.037) and body mass index (TMD, r = 0.478; www.ecmjournal.org
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alendronate-treated groups regardless of treatment duration (p = 0.112). The mean crack length had a tendency to be smallest in the long-term alendronate-treated group in comparison to the mid-term alendronate-treated group and controls (p = 0.076). Hence, crack surface density tended to be lower with long-term alendronate therapy in comparison with both the mid-term alendronate-treated group and controls (p = 0.080; Fig. 4 ).
Mechanical testing of single trabeculae
The Young's modulus, yield strength, ultimate stress, fracture stress, work to failure and toughness did not differ significantly among the three groups (Fig. 1) .
Mechanical testing of single trabeculae -univariate analysis
In a univariate analysis blind to treatment group, potential influencing confounders such as age, eroded surface or microdamage parameters were not significantly associated with mechanical parameters (Table 2) . TMD was the only univariate predictor of yield strength but demonstrated just a marginal negative association (coefficient -0.001, p = 0.036). Also, Young's modulus decreased with increasing degree of mineralisation as assessed by µCT (TMD coefficient -0.007, p = 0.028). In addition, another independent predictor of Young's modulus was body mass index demonstrating a negative association (coefficient -0.042, p = 0.026). However, increasing body mass index resulted in a higher work to failure of the tested trabeculae, which was not associated with another influencing parameter (coefficient 0.005, p = 0.002). Also, a higher body mass index of osteoporotic patients was associated with a higher ability to absorb energy prior to material failure in single trabeculae (toughness: coefficient 1.773, p = 0.027). Interestingly, TMD showed no independent association with either work to failure or toughness. Ultimate stress and fracture stress showed no association with any potentially influencing confounder (Table 2) .
Mechanical testing of single trabeculae -multivariate analysis
Bone and patient characteristics are interdependent and influence each other. Hence, mechanical properties might be influenced by a combination of bone and 3 . Bone mineralisation assessment using µCT. Tissue mineral density of a non-treated osteoporotic control case demonstrating low mineralisation and of a long-term alendronate-treated case demonstrating higher mineralisation at higher magnification (scanning electron microscopy for demonstration). TMD was higher in both mid-and longterm alendronate-treated patients compared to non-treated osteoporotic controls (p = 0.037). Comparisons were performed by t-test and ANOVA.
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patient predictors with an individually different impact. Thus, an additional multivariate analysis was performed including age, body mass index, TMD, eroded surface and microdamage indices. In a subsequent search for the best subset of influencing variables, the right-hand column of Table 2 shows the results of the multivariate analysis.
Compared to the univariate analysis Young's modulus still decreased with increasing body mass index. However, considering all potentially influencing parameters tested this association was highest just in combination with increasing crack length (Cr.Le) resulting in a higher Young's modulus (R 2 = 0.238). Furthermore, yield strength, ultimate stress and fracture stress correlated with increasing age and greater crack length in combination with a lower degree of mineralisation and eroded surface. However, work to failure was only associated with body mass index, while toughness was associated with higher body mass index, higher TMD, but most importantly a lower eroded surface representing potential stress raiser in a single trabeculae (Table 2 ).
Discussion
Bisphosphonates act by suppressing bone turnover; hence, a major concern is that this mechanism of preserving bone quantity in disease such as osteoporosis negatively affects the tissue characteristics leading to an accumulation of microdamage, higher mineralisation profiles and in turn deteriorated mechanical properties. Suppression of bone turnover is of particular concern for longterm bisphosphonate-treatment plans due to the recent unexplained occurrence of atypical femoral fractures in some patients (Shane et al., 2010; Donnelly et al., 2012) . Indeed, in vivo failure occurs through deformation and fracture of the entire vertebral body, and will depend on a multitude of factors including the bone quantity (i.e., BV/ TV) and bone quality (e.g., architecture, composition, damage, mechanical properties) at multiple length-scales. In the present study, we analyse the quality of the bone tissue at the trabecular level in patients with long-term alendronate treatment, mid-term alendronate treatment and non-treated controls with osteoporosis to determine whether alendronate treatment affects microdamage accumulation, tissue mineralisation and mechanical properties at the single trabeculae level.
One of the main effects of alendronate treatment is attributed to the suppressed rate of remodelling. Here, alendronate-treated patients demonstrated a significantly elevated degree of mineralisation than non-treated controls in vertebral bone. However, the mineralisation profile was not significantly different between the long-term and midterm alendronate treatments, which is in line with previous findings from other skeletal regions (Roschger et al., 2010; Black et al., 2012) .
Along with a shift to higher mineralisation, microdamage has been observed to accumulate with bisphosphonate treatment in many pre-clinical studies (Mashiba et al., 2000; Mashiba et al., 2001; Allen et al., 2006) . Clearly, the accumulation of microdamage is a concern because bisphosphonates act by suppressing bone turnover, which would reduce the number of remodelling events. However, here, an accumulation of microdamage was not found in the alendronate-treated patients. Long-term alendronatetreated patients even showed a tendency towards a lower amount of microdamage compared to non-treated controls. A similar study on iliac crest biopsies also found no association between bisphosphonate treatment duration and microdamage accumulation in humans (Chapurlat et al., 2007) . Microdamage should accumulate in regions with higher mineralisation in comparison to the surrounding tissue (Wasserman et al., 2005) . Given that Roschger et al. (Roschger et al., 2010) did not observe a higher incidence of abnormal highly mineralised bone areas after long-term bisphosphonate treatment in biopsies of human iliac crest bone, the lack of microdamage accumulation observed here in vertebral bodies is conceivable.
In accordance with the occurrence of microdamage, we were unable to find differences in the mechanical parameters of single trabeculae from alendronate-treated patients and non-treated osteoporotic controls. The mechanical properties of the single trabeculae here contrast with previous studies (computational and experimental in nature) using whole vertebral bodies that have found a higher vertebral compressive strength with bisphosphonate treatment (Mashiba et al., 2001; Keaveny et al., 2007) . When testing whole vertebral bodies, the cortical thickness and trabecular architecture affect the mechanical properties. In addition to strength, toughness is another important material property in relation to bone quality (Launey and Ritchie, 2009 ) and defines the ability to absorb energy in the process before material failure. In cases where bone turnover is affected, such as osteoporosis and the treatment of osteoporosis, bone strength and toughness can become impaired (Busse et al., 2009) . Despite the potential of bisphosphonates to reduce the occurrence of vertebral and non-vertebral fractures, preclinical animal studies have suggested that bisphosphonate treatments are associated with a reduced toughness (Mashiba et al., 2000; Mashiba et al., 2001; Komatsubara et al., 2003; Allen and Burr, 2007) . However, in the present study, the mid-term and long-term alendronate treatments did not result in a reduced toughness of single lumbar trabeculae in comparison to untreated osteoporotic controls.
Therefore, even though the mid-and long-term alendronate treatments had a slightly higher mineralisation, there was no change in mechanical properties or microdamage accumulation in comparison to non-treated osteoporotic bone. While the larger-scale vertebral features (such as cortical shell, trabecular architecture) may contribute to fracture risk reduction, the data presented here demonstrate that histologically the alendronate-treated bone and osteoporotic controls are different through the higher mineralisation profile and a smaller eroded surface, which are both established effects of the suppression of turnover induced by alendronate (Balena et al., 1993) . Thus, we theorise that even though the alendronate-treated individuals have a higher TMD, which should decrease their toughness, the reduction in resorption cavities may counteract the TMD to maintain the bone toughness after alendronate treatment. Indeed, in past studies, resorption cavities were identified to predict fracture risk independent M Krause et al.
Long-term alendronate treatment of aBMD because they decrease the overall bone area and may be considered as stress concentrations, where fractures can initiate (Garnero, 2000; Hernandez, 2008; Slyfield et al., 2012) . The univariate analysis between the mechanical properties and other possible predictors of fracture showed that the body mass index was associated with the mechanical properties. In clinical studies, the positive influence of the body mass index on fracture risk was primarily attributed to improved geometric strength and higher aBMD levels most probably due to adaptation to increased loading conditions (Beck et al., 2001; Beck et al., 2009 ). This was supported by our results as body mass index positively correlated with mineralisation data. However, the degree of mineralisation was not associated with toughness in the univariate analysis suggesting that body mass index has additional effects on bone material characteristics. As many of the bone characteristics are interrelated, the mechanical properties may be related to a joint contribution from multiple predictors. Thus, an additional multivariate analysis was performed. Here, toughness was influenced by a combination of TMD, body mass index and eroded surface. As discussed above, body mass index is commonly associated with improved geometric strength and higher aBMD levels (Beck et al., 2001; Beck et al., 2009) as well as TMD, in this study. Therefore, the multivariate analysis reflects the fact that combined changes in mineral density (through TMD or body mass index) and eroded surface influence the mechanical properties.
This study has some limitations. First, due to the retrospective study design, follow-up measurements were not possible, and there was no knowledge of the starting values for the parameters measured, which needs to be taken into account when looking at the restricted number of patients. However, the BioAsset study allowed a unique recruitment of patients with mid-and long-term alendronate treatments. The mechanical tests on single trabeculae from vertebral bodies also pose a few limitations. While testing material in its fresh state is optimal, special sample preparation techniques are required to singularise the trabeculae. In particular, the effect of hydrogen peroxide treatment to remove soft tissue is controversial; however, there is no strong evidence that the short hydrogen peroxide treatment affects the collagen or mineral properties due to the preservation of the collagenous matrix (osteoid) (Chng et al., 2005; DePaula et al., 2005; Joiner, 2007; Busse et al., 2009; Li et al., 2011) . Second, specimens were also tested dry, which could influence the mechanical properties. Dry testing particularly influences the strength and toughness by reducing the plasticity generated in the sample through deformation of the organic components. However, as all groups were tested in a dry state, a comparison is valid. Third, the materials properties and geometry could change throughout the cross-section of the trabeculae, which would pose another limitation to precisely measuring mechanical properties, but this mechanical testing technique has been implemented numerous times to investigate this small but important feature within the cancellous bone structure (Carretta et al., 2013; Ridha and Thurner, 2013) . Fourth, an additional contribution to the trabecular mechanical properties would be the inorganic component of bone. Indeed, increased levels of cross-linking within the organic component have been associated with fragility fractures (Saito et al., 2006) , as the cross-links presumably restrict deformation at small length-scales within bone (Zimmermann et al., 2011) . However, previous studies present in the literature do conflict over the effects of bisphosphonate treatment on the cross-linking profile within bone Boskey et al., 2009; Gourion-Arsiquaud et al., 2010; Donnelly et al., 2012) . Nonetheless, a drawback to the present study is that this level of the bone structure was not analysed.
In summary, here, we characterise the structure and mechanical properties of individual trabeculae from patients with long-term alendronate treatment, mid-term alendronate treatment and osteoporotic controls. From strength tests on single trabeculae, no differences were found between the alendronate-treated groups and the osteoporotic controls. The alendronate treatments did result in an elevated mineralisation profile in cancellous vertebral bone, which is a hallmark of bone turnover suppression due to treatment. However, the higher mineralisation profile's impact on the mechanical properties may be compensated by fewer resorption cavities (i.e., more bone is present or potential stress raisers are eliminated) in the alendronatetreated bone. This counterbalance was supported by a multivariate analysis showing that multiple factors, such as body mass index, bone mineralisation and eroded surface, can together influence the trabeculae's mechanical properties.
